Quick Answer
IGC Pharma, Inc. reported R&D Expense of $3.65 million for fiscal year 2025.
IGC Pharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.65M | -3.1% |
| 2024 | $3.77M | +9.0% |
| 2023 | $3.46M | +48.5% |
| 2022 | $2.33M | +150.8% |
| 2021 | $929.0K | -8.1% |
| 2020 | $1.01M | -19.5% |
| 2019 | $1.26M | +816.8% |
| 2018 | $137.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.59M | +73.2% | +86.6% |
| June 30, 2025 | $851.0K | -4.3% | -0.1% |
| December 31, 2024 | $852.0K | -5.6% | -7.1% |
| September 30, 2024 | $917.0K | -27.7% | +3.1% |
| June 30, 2024 | $889.0K | +19.0% | -1.6% |
| December 31, 2023 | $903.0K | +12.0% | -28.8% |
| September 30, 2023 | $1.27M | +65.1% | +69.7% |
| June 30, 2023 | $747.0K | -46.4% | -7.3% |
- IGC Pharma, Inc. showed a decrease of -3.1% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, IGC Pharma, Inc.’s r&d expense has grown by 2567.9% (from $137.0 thousand to $3.65 million).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: